ライフサイエンスコーパス: placebo group

1 nalidomide group and 12 [5%] patients in the placebo group).

2 fatal multifocal leukoencephalopathy in the placebo group).

3 plus zeaxanthin [L + Z] group and 120 in the placebo group).

4 nt (72 to the vandetanib group and 70 to the placebo group).

5 ated (19 to the liraglutide group; 21 to the placebo group).

6 , 130 in the topiramate group, and 66 in the placebo group).

7 ized (146 to the active group and 138 to the placebo group).

8 common in the canakinumab groups than in the placebo group.

9 e in quality of life score compared with the placebo group.

10 amide group and 10 individuals (3.6%) in the placebo group.

11 the neratinib group and 85 (6%) women in the placebo group.

12 27 deaths in the vaccine group and 22 in the placebo group.

13 nd 154 (81%) of 189 patients had died in the placebo group.

14 or group and 11 (11%) of 101 patients in the placebo group.

15 laparib group and eight (8%) patients in the placebo group.

16 for tenapanor groups and 7.87 mg/dl for the placebo group.

17 ving nintedanib versus 17.1% of those in the placebo group.

18 roup compared with 1326 (53%) of 2517 in the placebo group.

19 f the standard deviation of the score in the placebo group.

20 1156 to the treatment group and 1147 to the placebo group.

21 nd 1167 mL/min (IQR, 887-1449 mL/min) in the placebo group.

22 ) in the sorafenib group and 86 (48%) in the placebo group.

23 e of progression-free survival events in the placebo group.

24 min D3 + calcium group and 31.6 ng/mL in the placebo group.

25 in the combination-therapy group than in the placebo group.

26 ts in the tremelimumab group and none in the placebo group.

27 the tDCS group, and 5.8+/-7.9 points in the placebo group.

28 00-mg and 400-mg groups as compared with the placebo group.

29 up versus 96 (13%) of 747 individuals in the placebo group.

30 roup became nonreactive to CPT vs 18% in the placebo group.

31 ents in the metoprolol group and none in the placebo group.

32 sib group and 56 (72%) of 78 patients in the placebo group.

33 tide group and 412 (55%) participants in the placebo group.

34 any of the three intervention groups and the placebo group.

35 rtib group and 10.2 months (6.0-13.6) in the placebo group.

36 spectively, versus -1.4 points (0.41) in the placebo group.

37 n the oral insulin group and 62 (33%) in the placebo group.

38 e common in the pregabalin group than in the placebo group.

39 group versus 76.3 weeks (20.2-182.6) in the placebo group.

40 ificantly higher in the VD group than in the placebo group.

41 lower in the sotagliflozin group than in the placebo group.

42 igned to the minocycline group and 70 to the placebo group.

43 ore common in the imatinib group than in the placebo group.

44 SVG-ZEBOV-GP group, and in 59 (11.8%) in the placebo group.

45 e buparlisib group and 37 (47%) of 78 in the placebo group.

46 wo patients (1%) with hepatic failure in the placebo group.

47 e vandetanib group and 61 (87%) of 70 in the placebo group.

48 olvaptan group and in 8 of 685 (1.2%) in the placebo group.

49 pants from the vaccine group and 40 from the placebo group.

50 nd 88% fewer attacks, respectively, than the placebo group.

51 mepolizumab group, and 1.49 per year in the placebo group.

52 nd 9.4 months (5.3-13.1) for patients in the placebo group.

53 -free, as compared with 27% (3 of 11) in the placebo group.

54 three (7%, 1.4-18) of 45 participants in the placebo group.

55 adverse events compared with 49 (47%) in the placebo group.

56 tcome score in the mepolizumab compared with placebo groups.

57 anges occurred within the anakinra 2-week or placebo groups.

58 i was noted in the vaccine compared with the placebo group (0.149 mean episodes vs 0.146 mean episode

59 UA/day: 0.10, 3000 UA/day: 0.15) than in the placebo group (0.30).

60 peak (-0.68 +/- 0.13) when compared with the placebo group (-0.19 +/- 0.14; P = 0.0092).

61 ater in the angiotensin II group than in the placebo group (-1.75 vs. -1.28, P=0.01).

62 common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001).

63 n 750 mL [IQR 651 to 908]) compared with the placebo group (1126 mL [944-1185]; p=0.054).

64 sease-free survival events than those in the placebo group (116 vs 163 events; stratified hazard rati

65 ive delirium between the dexmedetomidine and placebo groups (12.2% [23 of 189] vs 11.4% [23 of 201],

66 ind randomized withdrawal period (127 in the placebo group; 126 in the asenapine group).

67 ids group, 142 (34%) in the multidomain plus placebo group, 134 (33%) in the polyunsaturated fatty ac

68 were more frequent in the KGF group than the placebo group (14 vs 5 events; odds ratio 4.9, 95% CI 1.

69 se events was similar in the rilotumumab and placebo groups (142 [48%] vs 149 [50%]).

70 ere similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 pati

71 d group (10.60; 95% CI, 8.82-12.36) than the placebo group (15.42; 95% CI, 13.24-17.80; P = .004).

72 cipants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74;

73 1 year were similar between the ramipril and placebo groups (162.1 +/- 70.5 mm(3) vs. 177.3 +/- 94.3

74 -treatment group was higher than that in the placebo group (177 of 257 participants [68.9%], P<0.001

75 ents in the combined ketamine groups and the placebo group (19.45% vs 19.82%, respectively; absolute

76 tis in the vaccine group and 87 cases in the placebo group (2.14 and 6.44 cases per 100 person-years,

77 of four active-treatment groups than in the placebo group (2.7% [two of 73]): 7.5 mg (11.3% [eight o

78 the ularitide group and 225 patients in the placebo group (21.7% vs. 21.0%; hazard ratio, 1.03; 96%

79 SMX group (29 of 215 [13.5%], P=0.03) or the placebo group (22 of 177 [12.4%], P=0.06).

80 ccurred more frequently in the sertraline vs placebo group (22.7% vs 10.4%, respectively; between-gro

81 ilator FEV1 after 12 weeks than did placebo (placebo group: 2246 mL [SD 768] at baseline vs 2261 mL [

82 s similar in the sotagliflozin group and the placebo group (3.0% [21 patients] and 2.4% [17], respect

83 ignificantly longer in the buparlisib versus placebo group (3.9 months [95% CI 2.8-4.2] vs 1.8 months

84 gnificantly different in the MABp1 group and placebo groups (47 [23%] vs 33 [32%], p=0.07).

85 he bone marrow mononuclear cells (48.7%) and placebo groups (51.6%) with no difference in regional LV

86 l, we randomly allocated 172 57 (33%) to the placebo group, 57 (33%) to the low-dose group, and 58 (3

87 d significantly greater than in those in the placebo group (6.8%, P<0.001 for both comparisons).

88 idence interval [CI], 4.08-6.14) than in the placebo group (6.91; 95% CI, 5.82-8.21; P = .03).

89 uent in the co-trimoxazole group than in the placebo group (8.1% vs 5.8%, p=0.03).

90 n 33.9 months, 95% CI 25.5-52.5) than in the placebo group (9.2 months, 7.4-13.6; HR 0.40, 95% CI 0.2

91 liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the m

92 80 mg/day group, compared with -0.1 for the placebo group, a significant difference.

93 hted ovum, and n=2; intrauterine death, n=2; placebo group: abortion, n=22; blighted ovum, n=1; intra

94 simendan group and 101 patients (61%) in the placebo group (absolute risk difference taking into acco

95 ndetanib group) or placebo plus gemcitabine (placebo group) according to pre-generated sequences prod

96 the dexamethasone group vs 75 (27.1%) in the placebo group achieved complete resolution of symptoms,

97 he dexamethasone group and 49 (17.7%) in the placebo group achieved complete resolution of symptoms,

98 he prednisolone group and 2.16 points in the placebo group (adjusted difference, -0.20; 95% CI, -0.40

99 s 3.4 in the pregabalin group and 3.0 in the placebo group (adjusted mean difference, 0.3; 95% CI, -0

100 s 3.7 in the pregabalin group and 3.1 in the placebo group (adjusted mean difference, 0.5; 95% confid

101 among men with AAMI in the testosterone and placebo groups (adjusted estimated difference, -0.07 [95

102 compared with nine (20%, 10-35) of 45 in the placebo group; adjusted IgG seroresponses were seen in 4

103 d excluding those who were randomised to the placebo group) after randomisation.

104 3 relamorelin dose groups compared with the placebo group (all P < .05, based on longitudinal analys

105 deaths in the rilotumumab group than in the placebo group; all patients in the rilotumumab group sub

106 he topiramate group, and 61% of those in the placebo group (amitriptyline vs. placebo, P=0.26; topira

107 worsened by 2.1 points (-0.6 to 4.8) in the placebo group, an adjusted mean difference of -3.5 point

108 ypothyroid Symptoms score (0.2+/-15.3 in the placebo group and 0.2+/-14.4 in the levothyroxine group;

109 f 34 with placebo; mean 0.4 [SD 0.79 for the placebo group and 0.85 for the opicinumab group] new Gd+

110 with 3646 liveborn infants (cohort 1, 999 in placebo group and 1010 in vaccine group; cohort 2, 805 i

111 Of these participants, 37 (93%) from the placebo group and 27 (66%) from the vaccine group develo

112 months was similar in each group (50 in the placebo group and 61 in the vaccine group).

113 and 1010 in vaccine group; cohort 2, 805 in placebo group and 798 in vaccine group).

114 , 172 (7%) were positive; 87 (7%) of 1267 in placebo group and 85 (7%) of 1245 in the MVA85A group (p

115 val was 13.3 months (95% CI 9.9-19.7) in the placebo group and not reached (95% CI 32.3-not evaluable

116 Five women died in the placebo group and three died in the vaccine group.

117 d during the course of the study (six in the placebo group and two in the sildenafil group); none of

118 e brexanolone group vs three patients in the placebo group) and somnolence (two vs none).

119 alidomide group and 41 [18%] patients in the placebo group) and thrombocytopenia (34 [15%] patients i

120 76 in the co-trimoxazole group and 77 in the placebo group), and 2053 (72%) received treatment contin

121 e sorafenib group and 50 (32%) of 156 in the placebo group, and 181 serious adverse events were repor

122 of the antipsychotic group versus 30% in the placebo group, and 23% versus 14% had a "good" response.

123 nfants until 90 days of age, compared with a placebo group, and did not affect infant immune response

124 abnormalities between the PfSPZ Vaccine and placebo groups, and only grade 1 (mild) local or systemi

125 compared with four (9%, 2.5-21) of 45 in the placebo group; and adjusted neutralising antibody serore

126 l had decreased to 5.48 mIU per liter in the placebo group, as compared with 3.63 mIU per liter in th

127 antly greater improvement in apathy than the placebo group at 4 weeks, 8 weeks, and 12 weeks.

128 mean DDR% was found in the MF group than the placebo group at 6 and 9 months in both subgroups, 5 to

129 found to be greater in the MF group than the placebo group at all visits.

130 ht loss in the liraglutide group than in the placebo group (at 5 weeks: median 3.7 kg [IQR 2.8 to 4.8

131 4 in the hydrocortisone group and 185 in the placebo group) at a median corrected age of 22 months (i

132 mite-impermeable (active group) or control (placebo group) bed encasings.

133 1 in the sertraline group and by -4.2 in the placebo group (between-group difference, 0.1 [95% CI, -1

134 score, 0 in the sertraline group vs 0 in the placebo group; between-group difference, 0 [95% CI, -10.

135 ance was slowed 4 hours postchallenge in the placebo group but not in the gammaT treatment group.

136 PCs decreased significantly at 1 year in the placebo group but not in the ramipril group.

137 the oral insulin group and 120 events in the placebo group, but no significant study-related adverse

138 However, in the placebo group, but not in the propranolol group, memory

139 as 27% lower in the active group than in the placebo group, but this did not reach significance (esti

140 roup versus five (16%) of 31 patients in the placebo group (chi(2)=0.06, p=0.81).

141 e events in five (16%) of 31 patients in the placebo group (chi(2)=7.8, p=0.0053, stopping rule not r

142 he open-label period and mania (11.9% of the placebo group compared with 4.0% of the asenapine group)

143 in the ozanezumab group vs four [3%] in the placebo group), depression (11 [7%] vs five [3%]), and d

144 Vitamin D and placebo groups did not differ in change in insulin sensi

145 One patient in the placebo group died (unrelated to study treatment).

146 ) in the iodine group and 91.5 (27.0) in the placebo group (difference -0.9, -6.8 to 5.0; p=0.74).

147 ne inhaled corticosteroids group than in the placebo group (difference between groups 0.071, 95% CI 0

148 higher in all tezepelumab groups than in the placebo group (difference, 0.12 liters with the low dose

149 min D3 + calcium group and 64 (5.58%) in the placebo group (difference, 1.69% [95% CI, -0.06% to 3.46

150 group vs 94 responders [34.6%] of 272 in the placebo group, difference 13.0% [95% CI 4.8-21.3]; p=0.0

151 ] in the KGF group vs 20 days [13-22] in the placebo group; difference -8 days, 95% CI -17 to -2; p=0

152 0] in the KGF group vs 11 days [8-16] in the placebo group; difference 6 days, 95% CI 2 to 14; p=0.00

153 roup, 3 in the high-dose group, and 1 in the placebo group discontinued the trial regimen because of

154 in the tremelimumab group vs two [1%] in the placebo group), dyspnoea (three [1%] vs two [1%]); respi

155 EP group and 3.5 per 100 person-years in the placebo group; efficacy 62.72% [95% CI -66.59 to 91.66])

156 EP group and 3.5 per 100 person-years in the placebo group; efficacy 72.50% [95% CI 5.98 to 91.95]; p

157 EP group and 2.5 per 100 person-years in the placebo group; efficacy 76.55% [95% CI 43.09 to 90.37]),

158 .52 in the evolocumab group and -0.93 in the placebo group), episodic memory (change in raw score, -1

159 o-trimoxazole group, compared with 34 in the placebo group (estimated mortality at 18 months 2.4% vs

160 arib group vs two [2%] of 99 patients in the placebo group), fatigue or asthenia (eight [4%] vs two [

161 hospitalizations was similar in the IIV and placebo group for infants >3 months of age.

162 0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 p

163 ed in the idelalisib group compared with the placebo group (grade >/=3 infections and infestations: 8

164 The placebo group had a mean+/-SD change in SCr from baselin

165 ; tension headache, n=1); one patient in the placebo group had a severe treatment-emergent adverse ev

166 ated fatty acids group, and 133 (32%) in the placebo group had at least one serious emerging adverse

167 ients in the MABp1 group and 11 (11%) in the placebo group had died, but no death was judged to be re

168 Natalizumab and placebo groups had similar incidences of adverse events

169 gorafenib group vs nine patients [5%] in the placebo group), hand-foot skin reaction (47 patients [13

170 de group and 28.9 months (23.0-36.3) for the placebo group (hazard ratio 0.57, 95% CI 0.46-0.71; p<0.

171 rlisib group and 3.5 months (2.2-3.7) in the placebo group (hazard ratio 0.65 [95% CI 0.45-0.95], nom

172 imumab group and 7.3 months (5.9-8.7) in the placebo group (hazard ratio 0.92 [95% CI 0.76-1.12], p=0

173 in the hormone therapy group vs 27.6% in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.94-1.0

174 .5% in the pertuzumab group and 98.4% in the placebo group (hazard ratio for an invasive-disease even

175 tuzumab group, as compared with 90.2% in the placebo group (hazard ratio for an invasive-disease even

176 the combination-therapy group and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.4

177 utamide group, as compared with 71.3% in the placebo group (hazard ratio for death, 0.77; 95% confide

178 longer in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P

179 the combination-therapy group and 39% in the placebo group (hazard ratio for relapse or death, 0.47;

180 eatment failures in 30 patients (60%) in the placebo group (hazard ratio, 0.25; 95% confidence interv

181 group and in 85 of 158 patients (54%) in the placebo group (hazard ratio, 0.78; 95% CI, 0.57 to 1.07;

182 tuzumab group and 210 patients (8.7%) in the placebo group (hazard ratio, 0.81; 95% confidence interv

183 .2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interv

184 group, as compared with 6.8% of those in the placebo group), headache (in 25.1% and 31.9%, vs. 16.9%)

185 sib group versus 4.0 months (3.1-5.2) in the placebo group (HR 0.76 [0.60-0.97], one-sided p=0.014).

186 arlisib group vs 4.5 months (3.3-5.0) in the placebo group (HR 0.80 [95% CI 0.68-0.94]; one-sided p=0

187 er significantly between the canakinumab and placebo groups (HR 0.94 [95% CI 0.83-1.06]; p=0.31).

188 laparib group vs 6.9 months [6.3-7.9] in the placebo group; HR 0.79 [97.5% CI 0.63-1.00]; p=0.026) or

189 in the eltrombopag group and one [2%] in the placebo group), hypokalaemia (six [6%] and two [4%]), pn

190 erence between the cannabidiol group and the placebo group in change in seizure frequency, -22.8 perc

191 rence between the levosimendan group and the placebo group in rates of hypotension or cardiac arrhyth

192 noncardiomyocytes (p = 0.0002) than did the placebo group in some regions of the heart.

193 ences between the levosimendan group and the placebo group in the durations of mechanical ventilation

194 ere no differences between latiglutenase and placebo groups in change from baseline in villous height

195 cant differences between the ganciclovir and placebo groups in duration of mechanical ventilation (5

196 quently in the cannabidiol group than in the placebo group included diarrhea, vomiting, fatigue, pyre

197 in the regorafenib group and two (1%) in the placebo group, including two patients (1%) with hepatic

198 baseline (decrease of 15%) compared with the placebo group (increase of 25%).

199 HRQL relative to baseline in either PPOIT or placebo groups, indicating that PPOIT was well tolerated

200 nts in the treatment group vs 13 [9%] in the placebo group), infections and infestations (25 [17%] vs

201 somnolence, n=1) and in two patients in the placebo group (infusion site pain, n=1; tension headache

202 the incidence of PCME between treatment and placebo groups is equivalent (p = 0.31).

203 in the pioglitazone group and by 0.29 in the placebo group (mean difference between treatment groups

204 D 57.8] in the KGF group, 43.1 [33.5] in the placebo group; mean difference 19.2, 95% CI -5.6 to 44.0

205 ned were enrolled, with 52 randomized to the placebo group (median age, 15 years; 40 male [76.9%]) an

206 sib group and 17 (22%) of 78 patients in the placebo group; most were caused by disease progression a

207 numab-treated group (n = 5 of 7) than in the placebo group (n = 0 of 13).

208 and 95% of active (n = 38) vs 78% and 83% of placebo group (n = 18).

209 to the XXMT treatment group (n = 22) or the placebo group (n = 22) in a 2-week trial.

210 d into two groups, a VD group (n = 29) and a placebo group (n = 29).

211 avir group (n=75 [80%]) than in those in the placebo group (n=10 [48%]; p=0.0049), mostly due to inje

212 /day group (n=36/74 [49%]), and those in the placebo group (n=34/72 [47%]).

213 313 children (iodine group, n=159; placebo group, n=154) were analysed for verbal and perfo

214 with WPPSI-III and 315 (iodine group, n=159; placebo group, n=156) for overall executive function wit

215 lus epirubicin, cisplatin, and capecitabine (placebo group; n=305).

216 ients in the ataluren group and those in the placebo group, neither in the intention-to-treat populat

217 group versus one (3%) of 31 patients in the placebo group (odds ratio 27.1 [95% CI 3.5-211.9], p=0.0

218 p as compared with 112 of 2498 (4.5%) in the placebo group (odds ratio, 1.02; 95% CI, 0.78 to 1.33; P

219 k 6 in the 80 mg/day group compared with the placebo group on the Abnormal Involuntary Movement Scale

220 0% in the hydrocortisone group vs 18% in the placebo group), or with moderate to severe neurodevelopm

221 e vaccine group and in 67.2% of those in the placebo group, or in the risk of serious adverse events

222 FPG were similar between the evolocumab and placebo groups over time in patients with diabetes, pred

223 n the simvastatin group vs three [4%] in the placebo group p=0.208).

224 in the azithromycin group and 7 (3%) in the placebo group (P = .08).

225 s in the pantoprazole group and 14.3% in the placebo group (p = 0.58).

226 ts in the pantoprazole group and 4.8% in the placebo group (p = 1.0).

227 er by 61%, 71%, and 66% than the rate in the placebo group (P<0.001 for all comparisons).

228 10-mg tofacitinib group versus 11.1% in the placebo group (P<0.001 for both comparisons with placebo

229 25% in the oral glucocorticoid doses in the placebo group (P<0.001 for both comparisons).

230 ectively, as compared with 2.4 points in the placebo group (P<0.001 for each dose vs. placebo), and e

231 ectively, as compared with 3.3 points in the placebo group (P<0.001 for each dose vs. placebo).

232 umab group, as compared with 1.8 days in the placebo group (P<0.001 for each dose vs. placebo).

233 the evolocumab group and -0.29+/-2.81 in the placebo group (P<0.001 for noninferiority; P=0.85 for su

234 utamide group, as compared with 13.4% in the placebo group (P<0.001).

235 in the tranexamic acid group and 7994 in the placebo group (P<0.001).

236 in the pooled canakinumab group than in the placebo group (p=0.0007 for trend across groups), but wa

237 cid group and in 2.8% of the patients in the placebo group (P=0.001), and seizures occurred in 0.7% a

238 in the tofacitinib group versus 8.2% in the placebo group (P=0.007); in the OCTAVE Induction 2 trial

239 nificant trend toward increased FMDBA in the placebo group (P=0.07) but not the rilonacept group (P=0

240 ) more in the elamipretide group than in the placebo group (P=0.11).

241 found in the sulindac group compared to the placebo group (*p = 0.018), indicative of a shortened cl

242 he acarbose group vs 150 [5%] of 3241 in the placebo group [p=0.0007]; safety population).

243 of 63 patients, 35% vs 11 of 63, 17% in the placebo group) (P = .04).

244 for the ganciclovir group vs 6 days for the placebo group, P = .16), incidence of secondary bacterem

245 12% for the ganciclovir group vs 15% for the placebo group, P = .54).

246 15% for the ganciclovir group vs 15% for the placebo group, P = .67), ICU length of stay (8 days for

247 for the ganciclovir group vs 8 days for the placebo group, P = .76), or mortality (12% for the ganci

248 up and 0.060 (95% CI, 0.048 to 0.076) in the placebo group; P = .06.

249 vaccine group vs 0.110 mean episodes in the placebo group; p=0.074).

250 479 (15%; 3.41 per 100 person-years) of 3250 placebo group participants (hazard ratio 0.98; 95% CI 0.

251 and -0.79 log10 units (-2.14 to 0.56) in the placebo group (point estimate of difference, 0 [95% CI,

252 In placebo group, post-treatment FAQLQ and FAIM remained un

253 were hen's egg sensitized versus 2.6% in the placebo group (primary outcome; relative risk, 2.20; 95%

254 the masitinib group vs one [2%] of 63 in the placebo group), rash (four [6%] vs none), and asthenia (

255 up compared with three (10%) patients in the placebo group (relative risk 3.93, 95% CI 1.31-11.81; p=

256 to have hen's egg allergy versus 0.6% in the placebo group (relative risk, 3.30; 95% CI, 0.35-31.32;

257 : 24 women in the iodine group and 28 in the placebo group reported adverse events (iodine group: abo

258 the vaccine group and 28 (55%) of 51 in the placebo group reported at least one adverse event.

259 n the anakinra 12-week, anakinra 2-week, and placebo groups, respectively (log-rank test P=0.10).

260 dosing was 1.7% and 1.6% in the vaccine and placebo groups, respectively, for a vaccine efficacy (VE

261 unts were 156 and 130 per hpf in the BOS and placebo groups, respectively.

262 and 5% (2%, 9%) in the Fe, MMN, Fe+MMN, and placebo groups, respectively.Daily iron supplementation

263 -0.036 +/- 0.544 mumol/L in vitamin B-12 and placebo groups, respectively; P < 0.001).

264 serious adverse event in the mepolizumab and placebo groups, respectively; the most common was asthma

265 in all treatment groups, most marked in the placebo group tapered off study drug.

266 to the 5-mg tofacitinib dose, and 64% in the placebo group that switched to the 10-mg tofacitinib dos

267 oup, 72% in the adalimumab group, 69% in the placebo group that switched to the 5-mg tofacitinib dose

268 zumab group as compared with the rate in the placebo group that underwent the 26-week prednisone tape

269 zumab group, as compared with 3296 mg in the placebo group that underwent the 26-week taper (P<0.001

270 izumab every other week, 22% of those in the placebo group that underwent the 26-week taper, and 25%

271 001 for both comparisons) and 3818 mg in the placebo group that underwent the 52-week taper (P<0.001

272 t the 26-week taper, and 25% of those in the placebo group that underwent the 52-week taper.

273 n the rucaparib group versus 28 (15%) in the placebo group, the most common of which were anaemia or

274 5% CI, 3.97 to 5.48) at 3 years, and for the placebo group, the score was 6.06 (95% CI, 5.23 to 6.88)

275 ompared with 90 [16%] of 570 patients in the placebo group; the most common serious adverse events (a

276 parlisib group versus 23 (16%) of 140 in the placebo group; the most frequent serious adverse events

277 8.3% in the vaccine group and in 9.1% in the placebo group); there were 27 deaths in the vaccine grou

278 brile neutropenia (48 [23%]), whereas in the placebo group they were neutropenia (99 [47%] of 209) an

279 tremelimumab group and 12 (6%) of 189 in the placebo group; those leading to the death of more than o

280 ious adverse events: one (2%) patient in the placebo group, three (5%) in the low-dose group, and two

281 in the 40-IU group and from 3.89 uses in the placebo group to 0.32 uses per month in the 60-IU group.

282 was reduced from 5.55 uses per month in the placebo group to 1.13 uses per month in the 40-IU group

283 ge 0-60) up to 3 weeks for olanzapine versus placebo groups using eight increasingly complex competin

284 s, improvement persisted in 1 patient in the placebo group versus 3 of 4 in the rituximab group, wher

285 occurred in three (0.2%) participants in the placebo group versus five (0.3%) in the vaccine group, s

286 % in an ebselen dose group compared with the placebo group was judged to be clinically relevant.

287 trimethoprim-sulfamethoxazole group and the placebo group was similar (mean [SD] change in weight-fo

288 7% in the hydrocortisone group vs 11% in the placebo group) was not statistically significantly diffe

289 at was at least twice as high as that in the placebo group were arthralgia, diarrhea, pruritus, vomit

290 The most common in the placebo group were constipation (two [2%] patients) and

291 raglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on trea

292 on adverse events in both the simtuzumab and placebo groups were dyspnoea, cough, upper respiratory t

293 worse adverse events in the rilotumumab and placebo groups were neutropenia (86 [29%] of 298 patient

294 ed to at least one dose of study drug); both placebo groups were pooled for assessment.

295 ccine group and 32 (78%) of 43 events in the placebo groups were reportedly suspected adverse events,

296 % of patients in the buparlisib group vs the placebo group) were hyperglycaemia (17 [22%] of 76 vs tw

297 in the rucaparib group vs 189 [100%] in the placebo group) were reported in 209 (56%) patients in th

298 ts in the neratinib group, compared with the placebo group, were diarrhoea (561 [40%] grade 3 and one

299 The placebo group will receive similar-looking placebo table

300 3% in the hydrocortisone group vs 70% in the placebo group), with mild neurodevelopmental impairment